View Filing Data

Document and Entity Information - shares	6 Months Ended
Document and Entity Information - shares	Jun. 30, 2017	Jul. 31, 2017
Document Entity Information [Abstract]
Entity Registrant Name	Minerva Neurosciences, Inc.
Entity Central Index Key	0001598646
Document Type	10-Q
Document Period End Date	Jun. 30, 2017
Amendment Flag	false
Current Fiscal Year End Date	--12-31
Entity Filer Category	Accelerated Filer
Document Fiscal Year Focus	2017
Document Fiscal Period Focus	Q2
Trading Symbol	NERV
Entity Common Stock, Shares Outstanding		42,509,003

Condensed Consolidated Balance Sheets (Unaudited) - USD ($)	Jun. 30, 2017	Dec. 31, 2016
Current assets
Cash and cash equivalents	$ 50,191,362	$ 82,980,609
Marketable securities	27,381,492
Restricted cash	80,000	80,000
Prepaid expenses and other current assets	421,693	803,241
Total current assets	78,074,547	83,863,850
Equipment, net	3,036	9,640
In-process research and development	34,200,000	34,200,000
Goodwill	14,869,399	14,869,399
Deferred public offering costs	232,980
Total assets	127,379,962	132,942,889
Current liabilities
Notes payable - current portion	5,066,500	4,853,753
Accounts payable	1,431,466	1,468,341
Accrued expenses and other current liabilities	1,443,439	815,813
Accrued collaborative expenses - related party	6,646,239	2,547,952
Total current liabilities	14,587,644	9,685,859
Notes payable - noncurrent	1,326,479	3,841,062
Deferred taxes	13,433,760	13,433,760
Total liabilities	29,347,883	26,960,681
Commitments and contingencies
Stockholders’ equity
Preferred stock; $0.0001 par value; 100,000,000 shares authorized; none issued or outstanding as of June 30, 2017 and December 31, 2016, respectively
Common stock; $0.0001 par value; 125,000,000 shares authorized; 36,759,003 and 35,024,002 shares issued and outstanding as of June 30, 2017 and December 31, 2016, respectively	3,676	3,502
Additional paid-in capital	251,311,357	238,836,940
Accumulated deficit	(153,282,954)	(132,858,234)
Total stockholders’ equity	98,032,079	105,982,208
Total liabilities and stockholders’ equity	$ 127,379,962	$ 132,942,889

Condensed Consolidated Balance Sheets (Parenthetical) (Unaudited) - $ / shares	Jun. 30, 2017	Dec. 31, 2016
Statement Of Financial Position [Abstract]
Preferred stock, par value (in dollars per share)	$ 0.0001	$ 0.0001
Preferred stock, shares authorized	100,000,000	100,000,000
Preferred stock, shares issued	0	0
Preferred stock, shares outstanding	0	0
Common stock, par value (in dollars per share)	$ 0.0001	$ 0.0001
Common stock, shares authorized	125,000,000	125,000,000
Common stock, shares issued	36,759,003	35,024,002
Common stock, shares outstanding	36,759,003	35,024,002

Condensed Consolidated Statements of Operations (Unaudited) - USD ($)	3 Months Ended		6 Months Ended
	Jun. 30, 2017	Jun. 30, 2016	Jun. 30, 2017	Jun. 30, 2016
Expenses
Research and development	$ 7,144,133	$ 2,714,298	$ 14,758,464	$ 8,089,162
General and administrative	2,601,408	2,250,206	5,472,150	4,632,248
Total expenses	9,745,541	4,964,504	20,230,614	12,721,410
Loss from operations	(9,745,541)	(4,964,504)	(20,230,614)	(12,721,410)
Foreign exchange losses	(20,115)	(15,462)	(36,798)	(24,974)
Investment income	155,657	34,613	214,319	66,977
Interest expense	(170,125)	(268,256)	(371,627)	(538,612)
Net loss	$ (9,780,124)	$ (5,213,609)	$ (20,424,720)	$ (13,218,019)
Net loss per share, basic and diluted	$ (0.27)	$ (0.18)	$ (0.57)	$ (0.47)
Weighted average shares outstanding, basic and diluted	36,719,541	29,122,411	36,048,300	28,162,561

Condensed Consolidated Statement of Changes in Stockholders' Equity (Unaudited) - USD ($)	Total	Public Offering	Private Placement	Common Stock	Common Stock Public Offering	Common Stock Private Placement	Additional Paid-in Capital	Additional Paid-in Capital Public Offering	Additional Paid-in Capital Private Placement	Accumulated Deficit
Balance at Dec. 31, 2015	$ 55,319,557			$ 2,472			$ 157,129,947			$ (101,812,862)
Balance (in shares) at Dec. 31, 2015				24,721,143
Exercise of common stock warrants	22,222,494			$ 385			22,222,109
Exercise of common stock warrants (in shares)				3,850,051
Issuance of common stock, net of issuance costs		$ 53,657,991	$ 999,999		$ 606	$ 18		$ 53,657,385	$ 999,981
Issuance of common stock, net of issuance costs (in shares)					6,052,631	181,488
Stock-based compensation	1,623,003						1,623,003
Net loss	(13,218,019)									(13,218,019)
Balance at Jun. 30, 2016	120,605,025			$ 3,481			235,632,425			(115,030,881)
Balance (in shares) at Jun. 30, 2016				34,805,313
Balance at Dec. 31, 2016	$ 105,982,208			$ 3,502			238,836,940			(132,858,234)
Balance (in shares) at Dec. 31, 2016	35,024,002			35,024,002
Exercise of common stock warrants	$ 9,356,833			$ 162			9,356,671
Exercise of common stock warrants (in shares)				1,621,073
Exercise of stock options	$ 576,174			$ 12			576,162
Exercise of stock options (in shares)	113,928			113,928
Stock-based compensation	$ 2,541,584						2,541,584
Net loss	(20,424,720)									(20,424,720)
Balance at Jun. 30, 2017	$ 98,032,079			$ 3,676			$ 251,311,357			$ (153,282,954)
Balance (in shares) at Jun. 30, 2017	36,759,003			36,759,003

Condensed Consolidated Statement of Changes in Stockholders' Equity (Unaudited) (Parenthetical)	6 Months Ended
	Jun. 30, 2016 USD ($)
Public Offering
Issuance cost	$ 3,842,004

Condensed Consolidated Statements of Cash Flows (Unaudited) - USD ($)	6 Months Ended
	Jun. 30, 2017	Jun. 30, 2016
Cash flows from operating activities:
Net loss	$ (20,424,720)	$ (13,218,019)
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation and amortization	6,604	8,639
Amortization of debt discount recorded as interest expense	124,130	186,133
(Accretion) amortization of marketable securities	(40,185)	90,734
Stock-based compensation expense	2,541,584	1,623,003
Changes in operating assets and liabilities
Prepaid expenses and other current assets	406,656	897,739
Accounts payable	(60,672)	(620,607)
Accrued expenses and other current liabilities	459,626	(1,071,437)
Accrued collaborative expenses	4,098,287
Net cash used in operating activities	(12,888,690)	(12,103,815)
Cash flows from investing activities:
Proceeds from the maturity and redemption of marketable securities		9,443,000
Purchase of marketable securities	(27,366,415)
Net cash (used in) provided by investing activities	(27,366,415)	9,443,000
Cash flows from financing activities:
Proceeds from sale of common stock in public offering		57,499,995
Costs paid in connection with public offering	(41,183)	(3,675,306)
Proceeds from exercise of common stock warrants	9,356,833	22,222,494
Proceeds from exercise of stock options	576,174
Repayments of notes payable	(2,425,966)
Proceeds from sale of common stock in private placement		999,999
Net cash provided by financing activities	7,465,858	77,047,182
Net (decrease) increase in cash and cash equivalents	(32,789,247)	74,386,367
Cash and cash equivalents
Beginning of period	82,980,609	14,284,054
End of period	50,191,362	88,670,421
Supplemental disclosure of non-cash financing activities
Deferred public offering costs included in accounts payable or in accrued expenses and other current liabilities	191,797	166,698
Supplemental disclosure of cash flow information
Cash paid for interest	$ 261,749	$ 352,500

Nature of Operations and Liquidity	6 Months Ended
Nature of Operations and Liquidity	Jun. 30, 2017
Nature Of Operations And Liquidity Disclosure [Abstract]
Nature of Operations and Liquidity	NOTE 1 — NATURE OF OPERATIONS AND LIQUIDITY Nature of Operations Minerva Neurosciences, Inc. (“Minerva” or the “Company”) is a clinical-stage biopharmaceutical company focused on the development and commercialization of a portfolio of product candidates to treat patients suffering from central nervous system (“CNS”) diseases. The Company has acquired or in-licensed four development-stage proprietary compounds that it believes have innovative mechanisms of action and therapeutic profiles that may potentially address the unmet needs of patients with these diseases. The Company’s lead product candidate is MIN-101, a compound the Company is developing for the treatment of schizophrenia. In addition, the Company’s portfolio includes MIN-202 (also known as JNJ-42847922), a compound the Company is co-developing with Janssen Pharmaceutica NV (“Janssen”), for the treatment of insomnia disorder and major depressive disorder (“MDD”); MIN-117, a compound the Company is developing for the treatment of MDD; and MIN-301, a compound the Company is developing for the treatment of Parkinson’s disease. In November 2013, the Company merged with Sonkei Pharmaceuticals Inc. (“Sonkei”), a clinical-stage biopharmaceutical company and, in February 2014, the Company acquired Mind-NRG, a pre-clinical-stage biopharmaceutical company. The Company refers to these transactions as the Sonkei Merger and Mind-NRG Acquisition, respectively. The Company holds licenses to MIN-101 and MIN-117 from Mitsubishi Tanabe Pharma Corporation (“MTPC”) with the rights to develop, sell and import MIN-101 and MIN-117 globally, excluding most of Asia. With the acquisition of Mind-NRG, the Company obtained exclusive rights to develop and commercialize MIN-301. The Company has also entered into a co-development and license agreement with Janssen, for the exclusive right to commercialize, and the co-exclusive right (with Janssen and its affiliates) to use and develop, MIN-202 in the European Union, Switzerland, Liechtenstein, Iceland and Norway (the “Minerva Territory”), subject to royalty payments to Janssen, and royalty rights for any sales outside the Minerva Territory. Liquidity The accompanying financial statements have been prepared as though the Company will continue as a going concern, which contemplates the realization of assets and satisfaction of liabilities in the normal course of business. The Company has limited capital resources and has incurred recurring operating losses and negative cash flows from operations since inception. As of June 30, 2017, the Company has an accumulated deficit of approximately $153.3 million and net cash used in operating activities was approximately $12.9 million during the six months ended June 30, 2017. Management expects to continue to incur operating losses and negative cash flows from operations. The Company has financed its operations to date from proceeds from the sale of common stock, warrants, loans and convertible promissory notes. The Company believes that its existing cash, cash equivalents and marketable securities will be sufficient to meet its cash commitments for at least the next 12 months after the date that the interim condensed financial statements are issued. The process of drug development can be costly and the timing and outcomes of clinical trials is uncertain. The assumptions upon which the Company has based its estimates are routinely evaluated and may be subject to change. The actual amount of the Company’s expenditures will vary depending upon a number of factors including but not limited to the design, timing and duration of future clinical trials, the progress of the Company’s research and development programs and the level of financial resources available. The Company has the ability to adjust its operating plan spending levels based on the timing of future clinical trials which will be predicated upon adequate funding to complete the trials. The Company will need to raise additional capital in order to continue to fund operations and fully fund later stage clinical development programs. The Company believes that it will be able to obtain additional working capital through equity financings or other arrangements to fund future operations; however, there can be no assurance that such additional financing, if available, can be obtained on terms acceptable to the Company. If the Company is unable to obtain such additional financing, future operations would need to be scaled back or discontinued.

Significant Accounting Policies

6 Months Ended

Jun. 30, 2017

Accounting Policies [Abstract]

Significant Accounting Policies

NOTE 2 — SIGNIFICANT ACCOUNTING POLICIES

Basis of presentation

The interim condensed consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America (“GAAP”) for interim reporting and the requirements of the Securities and Exchange Commission (“SEC”) in accordance with Regulation S-X, Rule 10-01. Under those rules, certain notes and financial information that are normally required for annual financial statements can be condensed or omitted. In the opinion of the Company’s management, the accompanying financial statements contain all adjustments (consisting of items of a normal and recurring nature) necessary to present fairly the financial position as of June 30, 2017, the results of operations for the three and six months ended June 30, 2017 and 2016 and cash flows for the six months ended June 30, 2017 and 2016. The results of operations for the three and six months ended June 30, 2017, are not necessarily indicative of the results to be expected for the full year. When preparing financial statements in conformity with GAAP, management must make estimates and assumptions that affect the reported amounts of assets and liabilities, disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of expenses during the reporting period. Actual results could differ from those estimates. The consolidated balance sheet as of December 31, 2016 was derived from the audited annual financial statements. The accompanying unaudited condensed consolidated financial statements and notes thereto should be read in conjunction with the audited consolidated financial statements for the year ended December 31, 2016 included in the Company’s Annual Report on Form 10-K filed with the SEC on March 13, 2017.

Consolidation

The accompanying consolidated financial statements include the results of the Company and its wholly-owned subsidiaries, Mind-NRG Sarl and Minerva Neurosciences Securities Corporation. Intercompany transactions have been eliminated.

Significant risks and uncertainties

The Company’s operations are subject to a number of factors that can affect its operating results and financial condition. Such factors include, but are not limited to: the results of clinical testing and trial activities of the Company’s products, the Company’s ability to obtain regulatory approval to market its products, competition from products manufactured and sold or being developed by other companies, the price of, and demand for, Company products, the Company’s ability to negotiate favorable licensing or other manufacturing and marketing agreements for its products, and the Company’s ability to raise capital.

The Company currently has no commercially approved products and there can be no assurance that the Company’s research and development will be successfully commercialized. Developing and commercializing a product requires significant time and capital and is subject to regulatory review and approval as well as competition from other biotechnology and pharmaceutical companies. The Company operates in an environment of rapid change and is dependent upon the continued services of its employees and consultants and obtaining and protecting intellectual property.

Use of estimates

The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosures of contingent assets and liabilities at the date of the financial statements and the reported amounts of expenses during the reporting period. Actual results could differ from those estimates.

Cash and cash equivalents

Cash equivalents include short-term, highly-liquid instruments, consisting of money market accounts and short-term investments with maturities from the date of purchase of 90 days or less. The majority of cash and cash equivalents are maintained with major financial institutions in North America. Deposits with these financial institutions may exceed the amount of insurance provided on such deposits; however, these deposits may be redeemed upon demand and, therefore, bear minimal risk.

Restricted cash

Cash accounts with any type of restriction are classified as restricted. The Company maintained restricted cash balances as collateral for corporate credit cards in the amount of $80,000 at June 30, 2017 and December 31, 2016.

Marketable securities

Marketable securities consist of corporate debt securities maturing in twelve months or less. Based on the Company’s intentions regarding its marketable securities, all marketable securities are classified as held-to-maturity and are carried at amortized cost. The Company’s investments in marketable securities are classified as Level 2 within the fair value hierarchy. As of June 30, 2017, remaining final maturities of marketable securities ranged from July 2017 to August 2017, with a weighted average remaining maturity of approximately 1 months. The following table provides the amortized cost basis, aggregate fair value, net unrealized (gains)/losses and the net carrying value of investments in held-to-maturity securities as of June 30, 2017:

	June 30, 2017
	Amortized		Aggregate		Net Unrealized		Net Carrying
	Cost		Fair Value		(Gains)/Losses		Value
Marketable securities:
Corporate bonds - current	$	27,381,492	$	27,380,584	$	908	$	27,381,492

Research and development costs

Costs incurred in connection with research and development activities are expensed as incurred. These costs include licensing fees to use certain technology in the Company’s research and development projects as well as fees paid to consultants and various entities that perform certain research and testing on behalf of the Company and costs related to salaries, benefits, bonuses and stock-based compensation granted to employees in research and development functions. The Company determines expenses related to clinical studies based on estimates of the services received and efforts expended pursuant to contracts with multiple research institutions and contract research organizations that conduct and manage clinical studies on its behalf. The financial terms of these agreements are subject to negotiation, vary from contract to contract and may result in uneven payment flows. Payments under some of these contracts depend on factors such as the successful enrollment of patients and the completion of clinical trial milestones. In accruing service fees, the Company estimates the time period over which services will be performed and the level of effort to be expended in each period. If the actual timing of the performance of services or the level of effort varies from the estimate, the accrual is adjusted accordingly. The expenses for some trials may be recognized on a straight-line basis if the expected costs are expected to be incurred ratably during the period. Payments for these activities are based on the terms of the individual arrangements, which may differ from the pattern of costs incurred, and are reflected in the consolidated financial statements as prepaid or accrued expenses.

In July 2014, the Company entered into a co-development and license agreement. The Company accounts for the co-development and license agreement as a joint risk-sharing collaboration in accordance with ASC 808, Collaboration Arrangements. Costs between the Company and the licensor with respect to each party’s share of development costs that have been incurred pursuant to the joint development plan are recorded within research and development expenses or general and administrative expenses, as applicable, in the accompanying consolidated financial statements due to the joint risk-sharing nature of the activities. During the three months ended June 30, 2017 and 2016, the Company recorded an expense of $3.6 million and a cost offset of $0.1 million, respectively, for certain development activities in accordance with the terms of the co-development agreement. During the six months ended June 30, 2017 and 2016, the Company recorded an expense of $6.6 million and a cost offset of $0.2 million, respectively, for certain development activities in accordance with the terms of the co-development agreement. The Company has included $6.6 million and $2.5 million in accrued collaborative expenses as of June 30, 2017 and December 31, 2016, respectively, related to this agreement. In June 2017, we entered into an Amendment to our Co-Development and License Agreement with Janssen, pursuant to which Janssen agreed to waive the remaining payments, including accrued and unpaid balances as of June 30, 2017, due from Minerva for Phase II development of MIN-202 as well as provide certain payments to the Company. The amendment was not effective as of June 30, 2017 as its effectiveness is contingent upon approval by the European Commission amongst other normal and customary closing conditions Refer to Note 11 – Subsequent Events for additional information.

In-process research and development

In-process research and development (“IPR&D”) assets represent capitalized incomplete research projects that the Company acquired through business combinations. Such assets are initially measured at their acquisition date fair values. The initial fair value of the research projects are recorded as intangible assets on the balance sheet, rather than expensed, regardless of whether these assets have an alternative future use.

The amounts capitalized are being accounted for as indefinite-lived intangible assets, subject to impairment testing, until completion or abandonment of research and development efforts associated with the project. An IPR&D asset is considered abandoned when it ceases to be used (that is, research and development efforts associated with the asset have ceased, and there are no plans to sell or license the asset or derive defensive value from the asset). At that point, the asset is considered to be disposed of and is written off. Upon successful completion of each project, the Company will make a determination about the then remaining useful life of the intangible asset and begin amortization. The Company tests its indefinite-lived intangibles, IPR&D assets, for impairment annually on November 30 and more frequently if events or changes in circumstances indicate that it is more likely than not that the asset is impaired. When testing indefinite-lived intangibles for impairment, the Company may assess qualitative factors for its indefinite-lived intangibles to determine whether it is more likely than not (that is, a likelihood of more than 50 percent) that the asset is impaired. Alternatively, the Company may bypass this qualitative assessment for some or all of its indefinite-lived intangibles and perform the quantitative impairment test that compares the fair value of the indefinite- lived intangible asset with the asset’s carrying amount. There was no impairment of IPR&D for the three and six months ended June 30, 2017 or 2016.

Stock-based compensation

The Company recognizes compensation cost relating to stock-based payment transactions using a fair-value measurement method, which requires all stock-based payments to employees, including grants of employee stock options, to be recognized in operating results as compensation expense based on fair value over the requisite service period of the awards. The Company determines the fair value of stock-based awards using the Black-Scholes option-pricing model which uses both historical and current market data to estimate fair value. The method incorporates various assumptions such as the risk-free interest rate, expected volatility, expected dividend yield, expected forfeiture rate and expected life of the options. The fair value of restricted stock units (“RSUs”) is equal to the closing price of the Company’s common stock on the date of grant.

The date of expense recognition for grants to non-employees is the earlier of the date at which a commitment for performance by the counterparty to earn the equity instrument is reached or the date at which the counterparty’s performance is complete. The Company determines the fair value of stock-based awards granted to non-employees similar to the way fair value of awards are determined for employees except that certain assumptions used in the Black-Scholes option-pricing model, such as expected life of the option, may be different and the fair value of each unvested award is adjusted at the end of each period for any change in fair value from the previous valuation until the award vests.

Foreign currency transactions

The Company’s functional currency is the US dollar. The Company pays certain vendor invoices in the respective foreign currency. The Company records an expense in US dollars at the time the liability is incurred. Changes in the applicable foreign currency rate between the date an expense is recorded and the payment date is recorded as a foreign currency gain or loss.

Loss per share

Basic loss per share excludes dilution and is computed by dividing net loss by the weighted-average number of shares of common stock outstanding for the period. Diluted loss per share reflects the potential dilution that could occur if securities or other contracts to issue common stock were exercised or converted into common stock or resulted in the issuance of common stock that shared in the earnings of the entity. The Company had a net loss in all periods presented, thus the inclusion of stock options and warrants would be anti-dilutive to net loss per share.

Concentration of credit risk

Financial instruments that potentially subject the Company to concentrations of credit risk are primarily cash, cash equivalents and marketable securities. The Company maintains its cash and cash equivalent balances in the form of business checking accounts and money market accounts, the balances of which, at times, may exceed federally insured limits. Exposure to cash and cash equivalents credit risk is reduced by placing such deposits with major financial institutions and monitoring their credit ratings. Marketable securities consist primarily of corporate bonds, with fixed interest rates. Exposure to credit risk of marketable securities is reduced by maintaining a diverse portfolio and monitoring their credit ratings.

Long-lived assets

The Company reviews the recoverability of all long-lived assets, including the related useful lives, whenever events or changes in circumstances indicate that the carrying amount of a long-lived asset might not be recoverable. If required, the Company compares the estimated undiscounted future net cash flows to the related asset’s carrying value to determine whether there has been an impairment. If an asset is considered impaired, the asset is written down to fair value, which is based either on discounted cash flows or appraised values in the period the impairment becomes known. The Company believes that all long-lived assets are recoverable, and no impairment was deemed necessary at June 30, 2017 and 2016.

Goodwill

The Company tests its goodwill for impairment annually, or whenever events or changes in circumstances indicate an impairment may have occurred, by comparing its reporting unit’s carrying value to its fair value. Impairment may result from, among other things, deterioration in the performance of the acquired business, adverse market conditions, adverse changes in applicable laws or regulations and a variety of other circumstances. If the Company determines that an impairment has occurred, it is required to record a write-down of the carrying value and charge the impairment as an operating expense in the period the determination is made. In evaluating the recoverability of the carrying value of goodwill, the Company must make assumptions regarding estimated future cash flows and other factors to determine the fair value of the acquired assets. Changes in strategy or market conditions could significantly impact those judgments in the future and require an adjustment to the recorded balances. The Company tests its goodwill for impairment as of November 30. There was no impairment of goodwill for the six months ended June 30, 2017 and 2016.

Deferred public offering costs

Deferred public offering costs include certain legal, accounting and other costs directly attributable to the Company’s public offering of common stock. Upon completion of the public offering on July 5, 2017, these amounts will be offset against the proceeds of the offering.

Segment information

Operating segments are defined as components of an enterprise (business activity from which it earns revenue and incurs expenses) about which discrete financial information is available and regularly reviewed by the chief operating decision maker in deciding how to allocate resources and in assessing performance. The Company’s chief decision maker, who is the Chief Executive Officer, reviews operating results to make decisions about allocating resources and assessing performance for the entire Company. The Company views its operations and manages its business as one operating segment.

Comprehensive Loss

The Company had no items of comprehensive loss other than its net loss for each period presented.

Recent Accounting Pronouncements

From time to time, new accounting pronouncements are issued by the Financial Accounting Standards Board (“FASB”) and are adopted by the Company as of the specified effective date.

Recently Adopted Accounting Pronouncements

In March 2016, the FASB issued Accounting Standards Update (“ASU”) No 2016-09, Compensation – Stock Compensation (Topic 718). The new standard simplifies several aspects of the accounting for employee share-based payment transactions, including the accounting for income taxes, forfeitures, and statutory tax withholding requirements, as well as classification in the statement of cash flows. Under this guidance, a company recognizes all excess tax benefits and tax deficiencies as income tax expense or benefit in the statement of operations. This change eliminates the notion of the additional paid-in capital pool and reduces the complexity in accounting for excess tax benefits and tax deficiencies. The new standard is effective for public companies for annual reporting periods beginning after December 15, 2016, including interim periods within those annual reporting periods; however, early adoption is allowed. The Company adopted the new standard on January 1, 2017. The adoption of this standard did not have a material impact on the Company’s consolidated financial statements.

Accounting Pronouncements Not Yet Adopted

In May 2014, the FASB issued ASU No. 2014-09, Revenue from Contracts with Customers (Topic 606) (“ASU 2014-09”). Subsequently, the FASB also issued ASU 2015-14, Revenue from Contracts with Customers (Topic 606) , which adjusted the effective date of ASU 2014-09; ASU No. 2016-08, Revenue from Contracts with Customers (Topic 606): Principal versus Agent Considerations (Reporting Revenue Gross versus Net) , which amends the principal-versus-agent implementation guidance and illustrations in ASU 2014-09; ASU No. 2016-10, Revenue from Contracts with Customers (Topic 606): Identifying Performance Obligations and Licensing , which clarifies identifying performance obligation and licensing implementation guidance and illustrations in ASU 2014-09; and ASU No. 2016-12, Revenue from Contracts with Customers (Topic 606): Narrow-Scope Improvements and Practical Expedients , which addresses implementation issues and is intended to reduce the cost and complexity of applying the new revenue standard in ASU 2014-09 (collectively, the “Revenue ASUs”).

The Revenue ASUs provide an accounting standard for a single comprehensive model for use in accounting for revenue arising from contracts with customers and supersedes most current revenue recognition guidance. The accounting standard is effective for interim and annual periods beginning after December 15, 2017, with an option to early adopt for interim and annual periods beginning after December 15, 2016. The guidance permits two methods of adoption: retrospectively to each prior reporting period presented (the full retrospective method), or retrospectively with the cumulative effect of initially applying the guidance recognized at the date of initial application (the modified retrospective method). The Company is currently evaluating the impact of the pending adoption of the new standard on the Company’s consolidated financial statements.

In February 2016, the FASB issued ASU No. 2016-02, Leases. The new standard establishes a right-of-use (ROU) model that requires a lessee to record a ROU asset and a lease liability on the balance sheet for all leases with terms longer than 12 months. Leases will be classified as either finance or operating, with classification affecting the pattern of expense recognition in the income statement. The new standard is effective for fiscal years beginning after December 15, 2018, including interim periods within those fiscal years. A modified retrospective transition approach is required for lessees for capital and operating leases existing at, or entered into after, the beginning of the earliest comparative period presented in the financial statements, with certain practical expedients available. Refer to Note 9, Commitments and Contingencies, for the Company's current lease commitments. The Company is currently evaluating the impact of the pending adoption of the new standard on the Company’s consolidated financial statements.

In August 2016, the FASB issued ASU No 2016-15, Statement of Cash Flows – Classification of Certain Cash Receipts and Cash Payments (Topic 230). The new standard clarifies the treatment of several cash flow categories. In addition, ASU 2016-15 clarifies that when cash receipts and cash payments have aspects of more than one class of cash flows and cannot be separated, classification will depend on the predominant source or use. This update is effective for annual periods beginning after December 15, 2017, and interim periods within those fiscal years, with early adoption permitted, including adoption in an interim period. The Company is currently evaluating the impact of the pending adoption of the new standard on the Company’s consolidated financial statements.

In January 2017, the FASB issued ASU No 2017-4, Intangibles — Goodwill and Other (Topic 350). The new standard simplifies the Test for Goodwill Impairment. This update is effective for annual periods beginning after December 15, 2019, and interim periods within those fiscal years, with early adoption permitted, including adoption in an interim period. The Company is currently evaluating the impact of the pending adoption of the new standard on the Company’s consolidated financial statements.

In March 2017, the FASB issued ASU No 2017-8, Receivables—Nonrefundable Fees and Other Costs (Subtopic 310-20) Premium Amortization on Purchased Callable Debt Securities. The new standard is intended to enhance the accounting for the amortization of premiums for purchased callable debt securities. This update is effective for annual periods beginning after December 15, 2018, and interim periods within those fiscal years, with early adoption permitted, including adoption in an interim period. The Company is currently evaluating the impact of the pending adoption of the new standard on the Company’s consolidated financial statements.

Accrued Expenses

6 Months Ended

Jun. 30, 2017

Payables And Accruals [Abstract]

Accrued Expenses

NOTE 3 — ACCRUED EXPENSES

Accrued expenses and other liabilities consist of the following:

	June 30, 2017		December 31, 2016
Research and development costs and other accrued expenses	$	416,229	$	574,290
Professional fees		527,048		192,000
Accrued bonus		398,574		-
Interest payable		35,270		49,523
Vacation payable		66,318		-
	$	1,443,439	$	815,813

Net Loss Per Share of Common Stock

6 Months Ended

Jun. 30, 2017

Earnings Per Share [Abstract]

Net Loss Per Share of Common Stock

NOTE 4 — NET LOSS PER SHARE OF COMMON STOCK

Diluted loss per share is the same as basic loss per share for all periods presented as the effects of potentially dilutive issuances were anti-dilutive given the Company’s net loss. Basic loss per share is computed by dividing net loss by the weighted-average number of common shares outstanding. The following table sets forth the computation of basic and diluted loss per share for common stockholders:

	Three Months Ended						Six Months Ended
	June 30,						June 30,
	2017			2016			2017			2016
Net loss	$	(9,780,124	)	$	(5,213,609	)	$	(20,424,720	)	$	(13,218,019	)
Weighted average shares of common stock outstanding		36,719,541			29,122,411			36,048,300			28,162,561
Net loss per share of common stock – basic and diluted	$	(0.27	)	$	(0.18	)	$	(0.57	)	$	(0.47	)

The following securities outstanding at June 30, 2017 and 2016 have been excluded from the calculation of weighted average shares outstanding as their effect on the calculation of loss per share is antidilutive:

	June 30,
	2017		2016
Common stock options		3,891,596		3,511,198
Restricted stock units		194,600	-
Common stock warrants		40,790		2,472,400

Debt

6 Months Ended

Jun. 30, 2017

Debt Disclosure [Abstract]

Debt

NOTE 5 — DEBT

Loan and Security Agreement

On January 16, 2015, the Company entered into a Loan and Security Agreement (as amended, the “Loan Agreement”) with Oxford Finance LLC (“Oxford”) and Silicon Valley Bank (“SVB” and, together with Oxford, the “Lenders”), providing for term loans to the Company in an aggregate principal amount of up to $15 million, in two tranches (the “Term Loans”).

The Company drew down the initial Term Loans in the aggregate principal amount of $10 million (the “Term A Loans”), on January 16, 2015. The Term A Loans bear interest at a fixed rate of 7.05% per annum. The Company believes that the Company's debt obligations accrue interest at rates which approximate prevailing market rates for instruments with similar characteristics and, accordingly, the carrying values for these instruments approximate fair value.

In August 2015, the Lenders and the Company entered into a First Amendment to the Loan Agreement, amending certain milestones related to the six month extension of the interest-only repayment period of the Term A Loans. By raising at least $30.0 million in gross capital (including at least $20.0 million from the sale of equity securities) and completing the first dosing of its Phase I/II clinical trial for MIN-117 prior to December 31, 2015, the Company achieved the interest-only milestones under the Loan Agreement and elected to extend the interest-only period an additional six months and reduce the repayment term by six months. Through August 1, 2016, the Company was obligated only to make monthly interest payments on the outstanding principal balance on the Term A Loans, followed by 24 months of equal principal and interest payments.

On or prior to March 31, 2016, the Company was permitted to borrow additional term loans in the aggregate principal amount up to $5 million, subject to the satisfaction of certain borrowing conditions, including the Company’s achievement of primary endpoints on its Phase IIa trials for MIN-117 and MIN-202 programs. In June 2016, the Company irrevocably elected not to borrow the additional $5 million available under the Term Loans.

The Company paid a facility fee of $75,000 for access to the Term Loans and will be required to pay a final payment of 5.1% of the total amount borrowed, which has been included as a component of the debt discount and is amortized to interest expense over the term of the loans. The outstanding Term A Loans and debt discount are as follows:

	June 30, 2017
Term A Loans	$	6,003,451
Less: debt discount and financing costs		(49,454	)
Less: current portion		(5,066,500	)
Accrued portion of final payment		438,982
Long-term portion	$	1,326,479

For the three months ended June 30, 2017 and 2016, the Company recognized interest expense of $0.2 million and $0.3 million respectively, including $0.1 million in both periods, related to the debt discount. For the six months ended June 30, 2017 and 2016, the Company recognized interest expense of $0.4 million and $0.5 million respectively, including $0.1 million and $0.2 million, respectively, related to the debt discount.

The Term Loans mature on August 1, 2018. The Company may prepay all, but not less than all, of the loaned amount upon 30 days’ advance notice to the Lenders, provided that the Company will be obligated to pay a prepayment fee equal to (i) 3% of the outstanding balance, if the loan is prepaid within 24 months of the funding date, (ii) 2% of the outstanding balance, if the loan is prepaid between 24 and 36 months of the funding date and (iii) 1% of the outstanding balance, if the loan is prepaid thereafter (each, a “Prepayment Fee”). The expected remaining repayment of the $10.0 million Term A loan principal is as follows:

2017		2,512,747
2018		3,490,704
Total Term A Loans	$	6,003,451

The Company’s obligations under the Loan Agreement are secured by a first priority security interest in substantially all of its assets, other than its intellectual property. The Company has also agreed not to pledge or otherwise encumber its intellectual property assets, except that it may grant certain exclusive and non-exclusive licenses of its intellectual property as set forth in the Loan Agreement. In addition, the Company pledged all of its equity interests in Minerva Neurosciences Securities Corporation and 65% of its equity interests in Mind-NRG, Sarl as security for its obligations under the Loan Agreement.

Upon the occurrence of certain events, including but not limited to the Company’s failure to satisfy its payment obligations under the Loan Agreement, the breach of certain of its other covenants under the Loan Agreement, or the occurrence of a material adverse change, the Lenders will have the right, among other remedies, to declare all principal and interest immediately due and payable, to take control of the Company’s cash in its SVB deposit account, and will have the right to receive the final payment fee and, if the payment of principal and interest is due prior to maturity, the applicable Prepayment Fee. As of June 30, 2017, the Company was in compliance with all covenants set forth in the Loan Agreement.

Co-Development and License Agreement	6 Months Ended
Co-Development and License Agreement	Jun. 30, 2017
Co Development And License Agreement Disclosure [Abstract]
Co-Development and License Agreement	NOTE 6 — CO-DEVELOPMENT AND LICENSE AGREEMENT On February 13, 2014, the Company signed a co-development and license agreement with Janssen, subject to the completion of an initial public offering and the payment of a $22.0 million license fee. Under the agreement, Janssen, the licensor, granted the Company an exclusive license, with the right to sublicense, in the Minerva Territory, under (i) certain patent and patent applications to sell products containing any orexin 2 compound, controlled by the licensor and claimed in a licensor patent right as an active ingredient and (ii) MIN-202 for any use in humans. In addition, upon regulatory approval in the Minerva Territory (and earlier if certain default events occur), the Company will have rights to manufacture MIN-202, also known as JNJ-42847922. The Company has granted to the licensor an exclusive license, with the right to sublicense, under all patent rights and know-how controlled by the Company related to MIN-202 to sell MIN-202 outside the Minerva Territory. In consideration of the licenses granted on July 7, 2014, the Company made a license fee payment of $22.0 million, which was included as a component of research and development expense in 2014. The Company will pay a quarterly royalty percentage to the licensor in the high single digits on aggregate net sales for MIN-202 products sold by the Company, its affiliates and sublicensees in the Minerva Territory. The licensor will pay a quarterly royalty percentage to the Company in the high single digits on aggregate net sales for MIN-202 products sold by the licensor outside the Minerva Territory. In accordance with the development agreement, the Company will pay 40% of MIN-202 development costs related to the joint development of any MIN-202 products. However, the Company’s share of aggregate development costs shall not exceed (i) $5.0 million for the period beginning from the effective date of the license and ending following the completion of certain Phase Ib clinical trials and animal toxicology studies, and (ii) $24.0 million for the period beginning from the effective date of the license and ending following the completion of certain Phase II clinical trials. The licensor has a right to opt out at the end of certain development milestones, with the first milestone being the completion of a single day Phase I clinical trial in patients with MDD. Upon opt out, the licensor will not have to fund further development of MIN-202 and the Minerva Territory will be expanded to also include all of North America. The Company would then owe the licensor a reduced royalty in the mid-single digits for all sales in the Minerva Territory. The Company has the right to terminate the license following certain development milestones, the first being completion of a certain Phase Ib clinical trial in patients with insomnia and certain toxicology studies in animals. If the Company terminates the license within 45 days of this milestone, the Company must pay a termination fee equal to $3.0 million. If the Company terminates the license at any time following the last development milestone involving a certain Phase IIb clinical trial, the Company will be entitled to a royalty in the mid-single digits from sales of MIN-202 by the licensor. The licensor may also terminate the agreement for the Company’s material breach or certain insolvency events, including if the Company is unable to fund its portion of the development costs. The Company accounts for the co-development and license agreement as a joint risk-sharing collaboration in accordance with ASC 808, Collaboration Arrangements. Payments between the Company and the licensor with respect to each party’s share of MIN-202 development costs that have been incurred pursuant to the joint development plan are recorded within research and development expenses or general and administrative expenses, as applicable, in the accompanying consolidated statements of operations due to the joint risk-sharing nature of the activities. The Company has included $6.6 million and $2.5 million in accrued collaborative expenses, as of June 30, 2017 and December 31, 2016, respectively, related to this agreement. In the six months ended June 30, 2017 and 2016, the Company paid $2.5 million and zero, respectively, related to development activities under this agreement. On July 6, 2016, the Company and Janssen agreed that “Decision Point 2” had been reached as defined under the co-development agreement. As neither party has exercised their right to withdraw from the agreement, the Company has paid Janssen $3.5 million and have incurred direct expenses of $0.3 million related to development activities under the current phase of development. During the three months ended June 30, 2017 and 2016, the Company recorded an expense of $3.6 million and a cost offset of $0.1 million, respectively, for certain development activities in accordance with the terms of the co-development agreement. During the six months ended June 30, 2017 and 2016, the Company recorded an expense of $6.6 million and a cost offset of $0.2 million, respectively, for certain development activities in accordance with the terms of the co-development agreement. A number of supportive activities and studies are underway in anticipation of the next phase of clinical trials with MIN-202 in both insomnia disorder and MDD. Refer to Note 11 – Subsequent Events for additional information regarding a pending amendment to the co-development and license agreement with Janssen.

Stockholders' Equity	6 Months Ended
Stockholders' Equity	Jun. 30, 2017
Stockholders Equity Note [Abstract]
Stockholders' Equity	NOTE 7 — STOCKHOLDERS’ EQUITY Warrant Exercises In January, February, June and December 2016 and in March 2017, certain investors in the Company’s March 2015 private placement exercised their warrants at an exercise price of $5.772 per share and received an aggregate of 5,673,758 shares of the Company’s common stock. The Company received gross proceeds of approximately $32.7 million from the exercise of these warrants. As of June 30, 2017, there are no remaining warrants outstanding under the Company’s March 2015 private placement. Public Offering of Common Stock On June 17, 2016, the Company closed a public offering of common stock, in which the Company issued and sold 6,052,631 shares of common stock at a public offering price of $9.50, for aggregate gross proceeds to the Company of $57.5 million. All of the shares issued and sold in this public offering were registered under the Securities Act pursuant to a registration statement on Form S-3 (File No. 333-205764) and a related prospectus and prospectus supplement, in each case filed with the Securities and Exchange Commission. The Company incurred $3.8 million in underwriting discounts and commissions and transaction costs, which have been included as a component of additional paid-in capital, resulting in net proceeds of $53.7 million. Refer to Note 11 – Subsequent Events for additional information regarding the public offering of common stock by the Company that closed on July 5, 2017. Private Placement of Common Stock On March 17, 2016, the Company entered into a common stock purchase agreement with a member of the Board of Directors, pursuant to which the Company, in a private placement, sold to the director an aggregate of 181,488 shares of the Company’s common stock, at a price per share of $5.51, for gross proceeds of approximately $1.0 million. Term Loan Warrants In connection with the Loan Agreement, the Company issued the Lenders warrants to purchase shares of its common stock upon its draw of each tranche of the Term Loans. The aggregate number of shares of common stock issuable upon exercise of the warrants is equal to 2.25% of the amount drawn of such tranche, divided by the average closing price per share of the Company’s common stock reported on the NASDAQ Global Market for the 10 consecutive trading days prior to the applicable draw. Upon the draw of the Term A Loans, the Company issued the Lenders warrants to purchase 40,790 shares of common stock at a per share exercise price of $5.516. The warrants are immediately exercisable upon issuance, and other than in connection with certain mergers or acquisitions, will expire on the ten-year anniversary of the date of issuance. The fair value of the warrants was estimated at $0.2 million using a Black-Scholes model and assuming: (i) expected volatility of 100.8%, (ii) risk free interest rate of 1.83%, (iii) an expected life of 10 years and (iv) no dividend payments. The fair value of the warrants was included as a discount to the Term A Loans and also as a component of additional paid-in capital and will be amortized to interest expense over the term of the loan. All such warrants were outstanding as of June 30, 2017.

Stock Option Plan and Stock-Based Compensation

6 Months Ended

Jun. 30, 2017

Disclosure Of Compensation Related Costs Sharebased Payments [Abstract]

Stock Option Plan and Stock-Based Compensation

NOTE 8 — STOCK OPTION PLAN AND STOCK-BASED COMPENSATION

In December 2013, the Company adopted the 2013 Equity Incentive Plan (the “Plan”), which provides for the issuance of options, stock appreciation rights, stock awards and stock units. On January 1, 2017, in accordance with the terms of the Plan, the total shares authorized for issuance under the plan increased by 750,000 to 5,781,333. This increase represents the lessor of 750,000 shares or 4% of the total shares outstanding calculated as of the end of the most recent fiscal year. The exercise price per share shall not be less than the fair value of the Company’s underlying common stock on the grant date and no option may have a term in excess of ten years. Stock option activity under the Plan is as follows:

	Shares Issuable Pursuant to Stock Options			Weighted- Average Exercise Price
Outstanding January 1, 2017		3,974,143		$	6.61

Granted		222,500		$	10.97
Exercised		(113,928	)	$	5.06
Forfeited		(191,119	)	$	7.58
Outstanding June 30, 2017		3,891,596		$	6.85
Exercisable June 30, 2017		2,186,774		$	5.98
Available for future grant		1,565,154

The weighted average grant-date fair value of stock options outstanding on June 30, 2017 was $5.26 per share. Total unrecognized compensation costs related to non-vested stock options at June 30, 2017 was approximately $8.7 million and is expected to be recognized within future operating results over a weighted-average period of 2.7 years. At June 30, 2017, the weighted average contractual term of the options outstanding is approximately 7.9 years. The intrinsic value of outstanding stock options at June 30, 2017 was $10.3 million.

The Company uses the Black Scholes model to estimate the fair value of stock options granted. For stock options granted during the six months ended June 30, 2017 and 2016, the Company utilized the following assumptions:

	2017		2016
Expected term (years)	5.5-6.25		5.5-6.25
Risk free interest rate	1.83-2.02%		1.17-1.52%
Volatility	79-84%		78-79%
Dividend yield		0%		0%
Weighted average grant date fair value per share of common stock	$	6.53	$	5.53

Stock-Based Awards Granted to Non-employees-The Company from time to time grants options to purchase common stock to non-employees for services rendered and records expense ratably over the vesting period of each award. The Company estimates the fair value of the stock options using the Black-Scholes valuation model at each reporting date. The Company granted 155,000 stock options to non-employees during the six months ended June 30, 2017. The Company recorded stock-based compensation expense for stock options granted to non-employees of $0.2 million during the six months ended June 30, 2017. There were no stock option grants made to non-employees made during the six months ended June 30, 2016.

For stock options granted to non-employees, the Company utilized the following assumptions:

	June 30, 2017
Expected term (years)	9.2-9.8
Risk free interest rate	2.26-2.30%
Volatility	111-113%
Dividend yield		0%
Weighted average reporting date fair value per share of common stock	$	8.05

The expected term of the employee-related options was estimated using the “simplified” method as defined by the Securities and Exchange Commission’s Staff Accounting Bulletin No. 107, Share-Based Payment. The volatility assumption was determined by examining the historical volatilities for industry peer companies, as the Company did not have sufficient trading history for its common stock. The risk-free interest rate assumption is based on the U.S. Treasury instruments whose term was consistent with the expected term of the options. The dividend assumption is based on the Company’s history and expectation of dividend payouts. The Company has never paid dividends on its common stock and does not anticipate paying dividends on its common stock in the foreseeable future. Accordingly, the Company has assumed no dividend yield for purposes of estimating the fair value of the options.

RSU activity under the Plan for the six months ended June 30, 2017 is as follows:

				Weighted-Average
				Grant Date
	RSUs			Fair Value
Unvested January 1, 2017		219,600		$	13.45
Granted		-		$	-
Vested		-		$	-
Forfeited		(25,000	)	$	13.45
Unvested June 30, 2017		194,600		$	13.45

RSUs awarded to employees generally vest one-fourth per year over four years from the anniversary of the date of grant, provided the employee remains continuously employed with the Company. Shares of the Company’s stock are delivered to the employee upon vesting, subject to payment of applicable withholding taxes. The fair value of RSUs is equal to the closing price of the Company’s common stock on the date of grant. Total unrecognized compensation costs related to non-vested RSUs at June 30, 2017 was approximately $2.2 million and is expected to be recognized within future operating results over a period of 3.5 years.

The Company recognized stock-based compensation expense for the six months ended June 30, 2017 and 2016 of $2.5 million and $1.6 million, respectively.

Commitments and Contingencies	6 Months Ended
Commitments and Contingencies	Jun. 30, 2017
Commitments And Contingencies Disclosure [Abstract]
Commitments and Contingencies	NOTE 9 — COMMITMENTS AND CONTINGENCIES In September 2014, the Company entered into a lease agreement for 4,043 square feet of office space in Waltham, MA. The term of the lease was approximately two years, and the Company was required to make monthly rental payments commencing December 2014. Estimated annual rent payable under this operating lease was approximately $0.1 million per year in each of the two years. In April 2016, the Company entered into an agreement to extend the term of the lease through March 31, 2018. Estimated annual rent payable under this agreement is approximately $0.1 million per year. From time to time, the Company may be subject to various legal proceedings and claims that arise in the ordinary course of the Company’s business activities. The Company is not aware of any claim or litigation, the outcome of which, if determined adversely to the Company, would have a material effect on the Company’s financial position or results of operations.

Related Party Transactions	6 Months Ended
Related Party Transactions	Jun. 30, 2017
Related Party Transactions [Abstract]
Related Party Transactions	NOTE 10 — RELATED PARTY TRANSACTIONS In January 2016, the Company entered into a services agreement with V-Watch SA (“V-Watch”), for approximately $105,000 for the use of V-Watch’s SomnoArt device for monitoring sleep in the MIN-101 Phase IIb and MIN-117 Phase IIa trials. The Company’s Chief Executive Officer is the chairman of the board of directors of V-Watch. Funds affiliated with Index Ventures, a stockholder of the Company, hold greater than 10% of the outstanding capital stock of V-Watch. During the six months ended June 30, 2017 and 2016, the Company recorded an expense of zero and $0.1 million, respectively, related to this agreement. Also refer to Note 6 – Co-Development and License agreement, Note 7 – Stockholder’s Equity and Note 11 – Subsequent Events for additional related party transactions.

Subsequent Events	6 Months Ended
Subsequent Events	Jun. 30, 2017
Subsequent Events [Abstract]
Subsequent Events	NOTE 11 — SUBSEQUENT EVENTS Amendment to Co-Development and License Agreement with Janssen In June 2017, the Company entered into an Amendment to its Co-Development and License Agreement with Janssen (the “Amendment”), pursuant to which Janssen agreed to forgo its right to royalties on MIN-202 insomnia sales in the Minerva Territory. The Company retained all of its rights to MIN-202 including commercialization of the molecule for the treatment of insomnia and as an as adjunctive therapy for MDD, which include an exclusive license in the European Union, Switzerland, Liechtenstein, Iceland and Norway, with royalties payable by the Company to Janssen. Royalties on sales outside of the Minerva Territory are payable by Janssen to the Company. Janssen also agreed to make an upfront payment to the Company of $30 million upon the effectiveness of the Amendment; a $20 million payment at the start of a Phase III insomnia trial for MIN-202; a $20 million payment when 50% of the patients are enrolled in this trial; and further agreed to waive the remaining payments, including accrued and unpaid balances as of June 30, 2017, due from the Company until completion of the Phase II development of MIN-202, which are estimated to total approximately $13 million inclusive of the $6.6 million in accrued collaborative expenses as of June 30, 2017. Upon the effectiveness of the Amendment, the Company will assume strategic control for clinical development of MIN-202 in insomnia and all financial responsibility for Phase III development costs for MIN-202 in insomnia. In connection with the Amendment, the Company also entered into a stock repurchase agreement with Johnson & Johnson Innovation-JJDC Inc. to repurchase all of the approximately 3.9 million shares of the Company’s stock held by Johnson & Johnson Innovation-JJDC Inc. at a per share price of $0.0001, for an aggregate purchase price of approximately $389. The effectiveness of the Amendment is contingent upon the closing of the stock repurchase agreement, and the closing of the stock repurchase agreement is contingent upon certain normal and customary closing conditions which include receiving either approval from the European Commission of the Amendment and the stock repurchase agreement or notification that the European Commission does not object to the Amendment and the stock repurchase agreement. The Company is currently evaluating the accounting treatment for the Amendment including aspects of revenue recognition treatment associated with the future payments that the Company expects to receive pursuant to the terms of the Agreement as well as for the waiver of remaining Phase II development costs pursuant to the Amendment. The Amendment automatically terminates if it is not effectuated prior to August 31, 2017 or if the stock repurchase agreement is terminated prior to the effectiveness of the Amendment. The stock repurchase agreement also automatically terminates if it is not effectuated prior to August 31, 2017. In the event that the Amendment is terminated, the Co-Development and License Agreement with Janssen will remain in full force and effect. Public Offering of Common Stock On July 5, 2017, the Company closed a public offering of its common stock, in which the Company issued and sold 5,750,000 shares of its common stock, including 750,000 shares sold pursuant to the underwriters’ full exercise of their option to purchase additional shares, at a public offering price of $7.75, for aggregate gross proceeds to the Company of $44.6 million. All of the shares issued and sold in this public offering were registered under the Securities Act pursuant to a registration statement on Form S-3 (File No. 333-205764) and a related prospectus and prospectus supplement, in each case filed with the Securities and Exchange Commission. The Company incurred $3.1 million in underwriting discounts and commissions and transaction costs, which will be included as a component of additional paid-in capital, resulting in net proceeds of approximately $41.5 million.

Significant Accounting Policies (Policies)

6 Months Ended

Jun. 30, 2017

Accounting Policies [Abstract]

Basis of Presentation

Basis of presentation

Consolidation

Significant Risks and Uncertainties

Significant risks and uncertainties

Use of Estimates

Use of estimates

Cash and Cash Equivalents

Cash and cash equivalents

Restricted Cash

Restricted cash

Marketable Securities

Marketable securities

	June 30, 2017
	Amortized		Aggregate		Net Unrealized		Net Carrying
	Cost		Fair Value		(Gains)/Losses		Value
Marketable securities:
Corporate bonds - current	$	27,381,492	$	27,380,584	$	908	$	27,381,492

Research and Development Costs

Research and development costs

In-Process Research and Development

In-process research and development

Stock-Based Compensation

Stock-based compensation

Foreign Currency Transactions

Foreign currency transactions

Loss Per Share

Loss per share

Concentration of Credit Risk

Concentration of credit risk

Long-Lived Assets

Long-lived assets

Goodwill

Deferred Public Offering Costs

Deferred public offering costs

Segment Information

Segment information

Comprehensive Loss

The Company had no items of comprehensive loss other than its net loss for each period presented.

Recent Accounting Pronouncements

From time to time, new accounting pronouncements are issued by the Financial Accounting Standards Board (“FASB”) and are adopted by the Company as of the specified effective date.

Recently Adopted Accounting Pronouncements

Accounting Pronouncements Not Yet Adopted

Significant Accounting Policies (Tables)

6 Months Ended

Jun. 30, 2017

Accounting Policies [Abstract]

Amortized Cost Basis, Aggregate Fair Value, Net Unrealized (Gains)/Losses and Net Carrying Value of Investments in Held-to-maturity Securities

The following table provides the amortized cost basis, aggregate fair value, net unrealized (gains)/losses and the net carrying value of investments in held-to-maturity securities as of June 30, 2017:

	June 30, 2017
	Amortized		Aggregate		Net Unrealized		Net Carrying
	Cost		Fair Value		(Gains)/Losses		Value
Marketable securities:
Corporate bonds - current	$	27,381,492	$	27,380,584	$	908	$	27,381,492

- Definition

Tabular disclosure of all investments in certain debt and equity securities for which the entity has the positive intent and ability to hold until maturity.

+ References + Details

Accrued Expenses (Tables)

6 Months Ended

Jun. 30, 2017

Payables And Accruals [Abstract]

Schedule of Accrued Expenses and Other Liabilities

Accrued expenses and other liabilities consist of the following:

	June 30, 2017		December 31, 2016
Research and development costs and other accrued expenses	$	416,229	$	574,290
Professional fees		527,048		192,000
Accrued bonus		398,574		-
Interest payable		35,270		49,523
Vacation payable		66,318		-
	$	1,443,439	$	815,813

Net Loss Per Share of Common Stock (Tables)

6 Months Ended

Jun. 30, 2017

Earnings Per Share [Abstract]

Computation of Basic and Diluted Loss Per Share

The following table sets forth the computation of basic and diluted loss per share for common stockholders:

	Three Months Ended						Six Months Ended
	June 30,						June 30,
	2017			2016			2017			2016
Net loss	$	(9,780,124	)	$	(5,213,609	)	$	(20,424,720	)	$	(13,218,019	)
Weighted average shares of common stock outstanding		36,719,541			29,122,411			36,048,300			28,162,561
Net loss per share of common stock – basic and diluted	$	(0.27	)	$	(0.18	)	$	(0.57	)	$	(0.47	)

Securities Excluded from Calculation of Weighted Average Shares Outstanding as their Effect is Antidilutive

	June 30,
	2017		2016
Common stock options		3,891,596		3,511,198
Restricted stock units		194,600	-
Common stock warrants		40,790		2,472,400

Debt (Tables)

6 Months Ended

Jun. 30, 2017

Debt Disclosure [Abstract]

Summary of Outstanding Term A Loans and Debt Discount

The outstanding Term A Loans and debt discount are as follows:

	June 30, 2017
Term A Loans	$	6,003,451
Less: debt discount and financing costs		(49,454	)
Less: current portion		(5,066,500	)
Accrued portion of final payment		438,982
Long-term portion	$	1,326,479

Expected Remaining Repayment of Term A Loan Principal

The expected remaining repayment of the $10.0 million Term A loan principal is as follows:

2017		2,512,747
2018		3,490,704
Total Term A Loans	$	6,003,451

Stock Option Plan and Stock-Based Compensation (Tables)

6 Months Ended

Jun. 30, 2017

Share Based Compensation Arrangement By Share Based Payment Award [Line Items]

Schedule of Stock Option Activity

Stock option activity under the Plan is as follows:

	Shares Issuable Pursuant to Stock Options			Weighted- Average Exercise Price
Outstanding January 1, 2017		3,974,143		$	6.61

Granted		222,500		$	10.97
Exercised		(113,928	)	$	5.06
Forfeited		(191,119	)	$	7.58
Outstanding June 30, 2017		3,891,596		$	6.85
Exercisable June 30, 2017		2,186,774		$	5.98
Available for future grant		1,565,154

Summary of Assumptions Used in Black Scholes Model to Estimate Fair Value of Stock Options

	2017		2016
Expected term (years)	5.5-6.25		5.5-6.25
Risk free interest rate	1.83-2.02%		1.17-1.52%
Volatility	79-84%		78-79%
Dividend yield		0%		0%
Weighted average grant date fair value per share of common stock	$	6.53	$	5.53

Schedule of RSU Activity

RSU activity under the Plan for the six months ended June 30, 2017 is as follows:

				Weighted-Average
				Grant Date
	RSUs			Fair Value
Unvested January 1, 2017		219,600		$	13.45
Granted		-		$	-
Vested		-		$	-
Forfeited		(25,000	)	$	13.45
Unvested June 30, 2017		194,600		$	13.45

Non-Employees Stock Options

Share Based Compensation Arrangement By Share Based Payment Award [Line Items]

Summary of Assumptions Used in Black Scholes Model to Estimate Fair Value of Stock Options

For stock options granted to non-employees, the Company utilized the following assumptions:

	June 30, 2017
Expected term (years)	9.2-9.8
Risk free interest rate	2.26-2.30%
Volatility	111-113%
Dividend yield		0%
Weighted average reporting date fair value per share of common stock	$	8.05

NATURE OF OPERATIONS AND LIQUIDITY - Additional Information (Details)	6 Months Ended
	Jun. 30, 2017 USD ($) License	Jun. 30, 2016 USD ($)	Dec. 31, 2016 USD ($)
Nature Of Operations And Liquidity [Line Items]
Accumulated deficit	$ (153,282,954)		$ (132,858,234)
Net cash used in operating activities	$ (12,888,690)	$ (12,103,815)
Development-stage Proprietary Compounds
Nature Of Operations And Liquidity [Line Items]
Number of licenses acquired \| License	4

SIGNIFICANT ACCOUNTING POLICIES - Additional Information (Details)	3 Months Ended		6 Months Ended
	Jun. 30, 2017 USD ($)	Jun. 30, 2016 USD ($)	Jun. 30, 2017 USD ($) Segment	Jun. 30, 2016 USD ($)	Dec. 31, 2016 USD ($)
Significant Accounting Policies [Line Items]
Restricted cash balances as collateral for corporate credit cards	$ 80,000		$ 80,000		$ 80,000
Marketable securities, weighted average remaining maturity			1 month
Research and development expense	7,144,133	$ 2,714,298	$ 14,758,464	$ 8,089,162
Impairment of Long-Lived Assets			$ 0	0
Impairment of goodwill	0	0
Number of operating segments \| Segment			1
In-Process Research and Development
Significant Accounting Policies [Line Items]
Asset impairment charges	0	0	$ 0	0
Janssen and JJDC \| Co-development and License Agreement
Significant Accounting Policies [Line Items]
Research and development expense	3,600,000	3,600,000	6,600,000	6,600,000
Janssen and JJDC \| Co-development and License Agreement \| MIN-202
Significant Accounting Policies [Line Items]
Development cost offset	100,000	$ 100,000	200,000	$ 200,000
Accrued collaborative expenses	$ 6,600,000		$ 6,600,000		$ 2,500,000

SIGNIFICANT ACCOUNTING POLICIES - Amortized Cost Basis, Aggregate Fair Value, Net Unrealized (Gains)/Losses and Net Carrying Value of Investments in Held-to-maturity Securities (Details) - Corporate Bonds - Current	Jun. 30, 2017 USD ($)
Schedule Of Held To Maturity Securities [Line Items]
Marketable securities, Amortized Cost	$ 27,381,492
Marketable securities, Aggregate Fair Value	27,380,584
Marketable securities, Net Unrealized (Gains)/Losses	908
Marketable securities, Net Carrying Value	$ 27,381,492

ACCRUED EXPENSES - Accrued Expenses and Other Liabilities (Details) - USD ($)	Jun. 30, 2017	Dec. 31, 2016
Payables And Accruals [Abstract]
Research and development costs and other accrued expenses	$ 416,229	$ 574,290
Professional fees	527,048	192,000
Accrued bonus	398,574
Interest payable	35,270	49,523
Vacation payable	66,318
Accrued expenses and other liabilities	$ 1,443,439	$ 815,813

NET LOSS PER SHARE OF COMMON STOCK - Computation of Basic and Diluted Loss Per Share (Details) - USD ($)	3 Months Ended		6 Months Ended
	Jun. 30, 2017	Jun. 30, 2016	Jun. 30, 2017	Jun. 30, 2016
Earnings Per Share [Abstract]
Net loss	$ (9,780,124)	$ (5,213,609)	$ (20,424,720)	$ (13,218,019)
Weighted average shares of common stock outstanding	36,719,541	29,122,411	36,048,300	28,162,561
Net loss per share, basic and diluted	$ (0.27)	$ (0.18)	$ (0.57)	$ (0.47)

NET LOSS PER SHARE OF COMMON STOCK - Securities Excluded from Calculation of Weighted Average Shares Outstanding as their Effect is Antidilutive (Details) - shares	6 Months Ended
	Jun. 30, 2017	Jun. 30, 2016
Common Stock Options
Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]
Securities outstanding excluded from the calculation of weighted average shares outstanding	3,891,596	3,511,198
Restricted Stock Units
Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]
Securities outstanding excluded from the calculation of weighted average shares outstanding	194,600
Common Stock Warrants
Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]
Securities outstanding excluded from the calculation of weighted average shares outstanding	40,790	2,472,400

DEBT - Additional Information (Details)			3 Months Ended		6 Months Ended
DEBT - Additional Information (Details)	Aug. 31, 2015 USD ($)	Jan. 16, 2015 USD ($) Tranche	Jun. 30, 2017 USD ($)	Jun. 30, 2016 USD ($)	Jun. 30, 2017 USD ($)	Jun. 30, 2016 USD ($)	Mar. 31, 2016 USD ($)
Debt Instrument [Line Items]
Amortization of debt discount recorded as interest expense					$ 124,130	$ 186,133
Loan and Security Agreement \| Term Loan
Debt Instrument [Line Items]
Aggregate principal amount		$ 15,000,000					$ 5,000,000
Number of tranches \| Tranche		2
Additional loan amount not borrowed				$ 5,000,000		5,000,000
Facility fee payment		$ 75,000
Final payment of term loan		5.10%
Amortization of debt discount recorded as interest expense			$ 100,000	100,000	$ 100,000	200,000
Term loans maturity date					Aug. 01, 2018
Advance notice period to the lenders					30 days
Term loan prepayment fee terms					(i) 3% of the outstanding balance, if the loan is prepaid within 24 months of the funding date, (ii) 2% of the outstanding balance, if the loan is prepaid between 24 and 36 months of the funding date and (iii) 1% of the outstanding balance, if the loan is prepaid thereafter (each, a “Prepayment Fee”).
Loan and Security Agreement \| Term Loan \| Mind-NRG, Sarl
Debt Instrument [Line Items]
Percentage of equity interests			65.00%		65.00%
Loan and Security Agreement \| Term Loan \| 24 months
Debt Instrument [Line Items]
Proportion of prepayment fees on outstanding balance					3.00%
Loan and Security Agreement \| Term Loan \| Between 24 and 36 months
Debt Instrument [Line Items]
Proportion of prepayment fees on outstanding balance					2.00%
Loan and Security Agreement \| Term Loan \| Prepaid Thereafter
Debt Instrument [Line Items]
Proportion of prepayment fees on outstanding balance					1.00%
Loan and Security Agreement \| Term Loan \| Term A Loans
Debt Instrument [Line Items]
Amount drew dawn during period		$ 10,000,000
Interest rate (as a percent)		7.05%
Minimum capital requirement	$ 30,000,000
Sale of equity securities	$ 20,000,000
Extended interest period for debt instrument					6 months
Reduced repayment period for debt instrument					6 months
Number of installments period					24 months
Interest expense			$ 200,000	$ 300,000	$ 400,000	$ 500,000

DEBT - Summary of Outstanding Term A Loans and Debt Discount (Details) - USD ($)	Jun. 30, 2017	Dec. 31, 2016
Debt Instrument [Line Items]
Term A Loans	$ 6,003,451
Less: current portion	(5,066,500)	$ (4,853,753)
Long-term portion	1,326,479	$ 3,841,062
Term Loan \| Term A Loans
Debt Instrument [Line Items]
Term A Loans	6,003,451
Less: debt discount and financing costs	(49,454)
Less: current portion	(5,066,500)
Accrued portion of final payment	438,982
Long-term portion	$ 1,326,479

DEBT - Expected Remaining Repayment of Term A Loan Principal (Details)	Jun. 30, 2017 USD ($)
Debt Instrument [Line Items]
Total Term A Loans	$ 6,003,451
Term Loan \| Term A Loans
Debt Instrument [Line Items]
2017	2,512,747
2018	3,490,704
Total Term A Loans	$ 6,003,451

CO-DEVELOPMENT AND LICENSE AGREEMENT - Additional Information (Details) - USD ($)				3 Months Ended		6 Months Ended
	Jul. 06, 2016	Jul. 07, 2014	Feb. 13, 2014	Jun. 30, 2017	Jun. 30, 2016	Jun. 30, 2017	Jun. 30, 2016	Dec. 31, 2016
Co-development and license agreement
Research and development expense				$ 7,144,133	$ 2,714,298	$ 14,758,464	$ 8,089,162
MIN-202 \| Co-development and License Agreement \| Phase Ib Clinical Trials \| Maximum
Co-development and license agreement
Share of aggregate development cost following completion of Phase Ib clinical trials and animal toxicology studies			$ 5,000,000
MIN-202 \| Co-development and License Agreement \| Phase II Clinical Trials \| Maximum
Co-development and license agreement
Share of aggregate development cost following completion of Phase Ib clinical trials and animal toxicology studies			$ 24,000,000
Janssen \| MIN-202 \| Co-development and License Agreement
Co-development and license agreement
Payment of license fee		$ 22,000,000
Percentage of development costs related to joint development of products			40.00%
Period within which agreement is terminated related to Phase Ib clinical trials milestone			45 days
Termination fee related to Phase Ib clinical trial milestone			$ 3,000,000
Accrued collaborative expenses				6,600,000		6,600,000		$ 2,500,000
Payment of development costs	$ 3,500,000					2,500,000	0
Direct expenses incurred	$ 300,000
Research and development expense				3,600,000	3,600,000	6,600,000	6,600,000
Development cost offset				$ 100,000	$ 100,000	$ 200,000	$ 200,000

STOCKHOLDERS' EQUITY - Warrants Exercises - Additional Information (Details) - USD ($)	6 Months Ended		15 Months Ended
	Jun. 30, 2017	Jun. 30, 2016	Mar. 31, 2017
Class Of Warrant Or Right [Line Items]
Proceeds from exercise of warrants	$ 9,356,833	$ 22,222,494
Private Placement \| Warrants
Class Of Warrant Or Right [Line Items]
Common stock exercise price per share			$ 5.772
Shares of common stock to purchase by warrant			5,673,758
Proceeds from exercise of warrants			$ 32,700,000
Warrants outstanding	0

STOCKHOLDERS' EQUITY - Public Offering of Common Stock - Additional Information (Details) - USD ($)		6 Months Ended
	Jun. 17, 2016	Jun. 30, 2017	Jun. 30, 2016
Class Of Stock [Line Items]
Proceeds from sale of common stock in public offering			$ 57,499,995
Underwriting discounts and commissions and transaction costs		$ 41,183	$ 3,675,306
Public Offering
Class Of Stock [Line Items]
Shares of common stock issued	6,052,631
Share price (in dollars per share)	$ 9.50
Proceeds from sale of common stock in public offering	$ 57,500,000
Underwriting discounts and commissions and transaction costs	3,800,000
Net proceeds from issuance of common stock	$ 53,700,000

STOCKHOLDERS' EQUITY - Private Placement of Common Stock - Additional Information (Details) - USD ($)		6 Months Ended
	Mar. 17, 2016	Jun. 30, 2016
Class Of Stock [Line Items]
Gross proceeds from issuance of common stock and warrants	$ 1,000,000	$ 999,999
Common Stock \| Private Placement
Class Of Stock [Line Items]
Shares of common stock issued	181,488	181,488
Sale of common stock, price per share	$ 5.51

STOCKHOLDERS' EQUITY - Term Loan Warrants - Additional Information (Details) $ / shares in Units, $ in Millions	Jan. 16, 2015 USD ($) TradingDay $ / shares shares
Class Of Warrant Or Right [Line Items]
Fair value of warrants estimated \| $	$ 0.2
Warrant
Class Of Warrant Or Right [Line Items]
Expiration anniversary date of issuance	10 years
Expected stock price volatility (as a percent)	100.80%
Risk-free interest rate (as a percent)	1.83%
Expected life	10 years
Expected dividend	$ 0
Term Loan
Class Of Warrant Or Right [Line Items]
Aggregate number of shares of Common Stock issuable	2.25%
Consecutive trading days \| TradingDay	10
Term Loan \| Term A Loans
Class Of Warrant Or Right [Line Items]
Shares of common stock to purchase by warrant \| shares	40,790
Common stock exercise price per share	$ 5.516

STOCK OPTION PLAN AND STOCK-BASED COMPENSATION - Additional Information (Details) - USD ($) $ / shares in Units, $ in Millions		6 Months Ended		12 Months Ended
	Jan. 02, 2017	Jun. 30, 2017	Jun. 30, 2016	Dec. 31, 2016	Jan. 01, 2017
Stock Option Plan and Stock-Based Compensation
Fair value of common stock on grant date (in dollars per share)		$ 5.26
Weighted average contractual term of the options outstanding		7 years 10 months 25 days
Intrinsic value of outstanding stock options (in dollars)		$ 10.3
Stock options granted		222,500
Stock-based compensation expense		$ 2.5	$ 1.6
Dividend yield (as a percent)		0.00%	0.00%
Employee Stock Option
Stock Option Plan and Stock-Based Compensation
Total unrecognized compensation costs		$ 8.7
Weighted-average period over which unrecognized compensation costs is expected to be recognized		2 years 8 months 12 days
Non-Employees Stock Options
Stock Option Plan and Stock-Based Compensation
Stock options granted		155,000	0
Stock-based compensation expense		$ 0.2
Dividend yield (as a percent)		0.00%
RSUs
Stock Option Plan and Stock-Based Compensation
Total unrecognized compensation costs		$ 2.2
Weighted-average period over which unrecognized compensation costs is expected to be recognized		3 years 6 months
Vesting rights percentage		25.00%
Vesting period		4 years
Description of vesting rights		RSUs awarded to employees generally vest one-fourth per year over four years from the anniversary of the date of grant
2013 Equity Incentive Plan
Stock Option Plan and Stock-Based Compensation
Increase in number of shares authorized for issuance				750,000
Shares authorized for issuance under the plan					5,781,333
Additional shares authorized for issuance under the plan as percentage of total shares outstanding		4.00%
Maximum \| 2013 Equity Incentive Plan \| Employee Stock Option
Stock Option Plan and Stock-Based Compensation
Term of share-based award	10 years

STOCK OPTION PLAN AND STOCK-BASED COMPENSATION - Stock Option Activity (Details)	6 Months Ended
	Jun. 30, 2017 $ / shares shares
Shares Issuable Pursuant to Stock Options
Outstanding at the beginning of period (in shares)	3,974,143
Granted (in shares)	222,500
Exercised (in shares)	(113,928)
Forfeited (in shares)	(191,119)
Outstanding at the end of the period (in shares)	3,891,596
Exercisable at the end of the period (in shares)	2,186,774
Available for future grant (in shares)	1,565,154
Weighted-Average Exercise Price
Outstanding at the beginning of period (in dollars per share) \| $ / shares	$ 6.61
Granted (in dollars per share) \| $ / shares	10.97
Exercised (in dollars per share) \| $ / shares	5.06
Forfeited (in dollars per share) \| $ / shares	7.58
Outstanding at the end of the period (in dollars per share) \| $ / shares	6.85
Exercisable at the end of the period (in dollars per share) \| $ / shares	$ 5.98

STOCK OPTION PLAN AND STOCK-BASED COMPENSATION - Summary of Assumptions Used in Black Scholes Model to Estimate Fair Value of Stock Options (Details) - $ / shares	6 Months Ended
	Jun. 30, 2017	Jun. 30, 2016
Stock Option Plan and Stock-Based Compensation
Risk free interest rate, Minimum	1.83%	1.17%
Risk free interest rate, Maximum	2.02%	1.52%
Volatility, Minimum	79.00%	78.00%
Volatility, Maximum	84.00%	79.00%
Dividend yield	0.00%	0.00%
Weighted average grant date fair value per share of common stock	$ 6.53	$ 5.53
Minimum
Stock Option Plan and Stock-Based Compensation
Expected term (years)	5 years 6 months	5 years 6 months
Maximum
Stock Option Plan and Stock-Based Compensation
Expected term (years)	6 years 2 months 30 days	6 years 2 months 30 days
Non-Employees Stock Options
Stock Option Plan and Stock-Based Compensation
Risk free interest rate, Minimum	2.26%
Risk free interest rate, Maximum	2.30%
Volatility, Minimum	111.00%
Volatility, Maximum	113.00%
Dividend yield	0.00%
Weighted average reporting date fair value per share of common stock	$ 8.05
Non-Employees Stock Options \| Minimum
Stock Option Plan and Stock-Based Compensation
Expected term (years)	9 years 2 months 12 days
Non-Employees Stock Options \| Maximum
Stock Option Plan and Stock-Based Compensation
Expected term (years)	9 years 9 months 18 days

STOCK OPTION PLAN AND STOCK-BASED COMPENSATION - Schedule of RSU Activity (Details) - RSUs - $ / shares	6 Months Ended
	Jun. 30, 2017	Dec. 31, 2016
Stock Options
Unvested at the beginning of the period (in shares)	219,600
Granted (in shares)	0
Vested (in shares)	0
Forfeited (in shares)	(25,000)
Unvested at the end of the period (in shares)	194,600
Weighted-Average Grant Date Fair Value
Unvested, Weighted-Average Grant Date Fair Value	$ 13.45	$ 13.45
Forfeited (in dollars per share)	$ 13.45

COMMITMENTS AND CONTINGENCIES - Additional Information (Details)	1 Months Ended
	Apr. 30, 2016 USD ($)	Sep. 30, 2014 USD ($) ft²
Commitments And Contingencies Disclosure [Abstract]
Area of office space \| ft²		4,043
Estimated annual rent payable \| $	$ 100,000	$ 100,000
Lease term		2 years
Extended lease agreement date	Mar. 31, 2018

RELATED PARTY TRANSACTIONS - Additional Information (Details) - V - Watch SA - USD ($)	1 Months Ended	6 Months Ended
	Jan. 31, 2016	Jun. 30, 2017	Jun. 30, 2016
Related Party Transaction [Line Items]
Services agreement	$ 105,000
Related party expenses		$ 0	$ 100,000
Minimum
Related Party Transaction [Line Items]
Percentage of outstanding capital stock	10.00%

SUBSEQUENT EVENTS - Additional Information (Details) - USD ($)			1 Months Ended	6 Months Ended
	Jul. 05, 2017	Jun. 17, 2016	Jun. 30, 2017	Jun. 30, 2017	Jun. 30, 2016
Subsequent Event [Line Items]
Proceeds from sale of common stock in public offering					$ 57,499,995
Underwriting discounts and commissions and transaction costs				$ 41,183	$ 3,675,306
Public Offering
Subsequent Event [Line Items]
Shares of common stock issued		6,052,631
Share price (in dollars per share)		$ 9.50
Proceeds from sale of common stock in public offering		$ 57,500,000
Underwriting discounts and commissions and transaction costs		3,800,000
Net proceeds from issuance of common stock		$ 53,700,000
Public Offering \| Subsequent Event
Subsequent Event [Line Items]
Shares of common stock issued	5,750,000
Share price (in dollars per share)	$ 7.75
Proceeds from sale of common stock in public offering	$ 44,600,000
Underwriting discounts and commissions and transaction costs	3,100,000
Net proceeds from issuance of common stock	$ 41,500,000
Exercise of Underwriters \| Subsequent Event
Subsequent Event [Line Items]
Shares of common stock issued	750,000
Johnson & Johnson Innovation-JJDC Inc
Subsequent Event [Line Items]
Stock repurchased			3,900,000
Aggregate purchase price			$ 389
Stock repurchased price per share			$ 0.0001
License and stock repurchase agreement termination description			The Amendment automatically terminates if it is not effectuated prior to August 31, 2017 or if the stock repurchase agreement is terminated prior to the effectiveness of the Amendment. The stock repurchase agreement also automatically terminates if it is not effectuated prior to August 31, 2017. In the event that the Amendment is terminated, the Co-Development and License Agreement with Janssen will remain in full force and effect.
MIN-202 \| Janssen \| Amendment to Co-Development and License Agreement
Subsequent Event [Line Items]
Upfront payment			$ 30,000,000
MIN-202 \| Janssen \| Amendment to Co-Development and License Agreement \| Phase III Insomnia Trail
Subsequent Event [Line Items]
Payment start of Phase			20,000,000
Payment upon enrollment of patients			$ 20,000,000
Percentage of patients to be enrolled			50.00%
MIN-202 \| Janssen \| Amendment to Co-Development and License Agreement \| Phase II Clinical Trials
Subsequent Event [Line Items]
Waive of remaining payments			$ 13,000,000
Accrued collaborative expenses			$ 6,600,000	$ 6,600,000